FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206647534> ?p ?o ?g. }

• W3206647534 endingPage "e002919" @default.
• W3206647534 startingPage "e002919" @default.
• W3206647534 abstract "Immune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) promotes intratumoral T cell infiltration but induces upregulation of PD-1 and programmed death ligand-1 (PD-L1) within the prostate TME. Combined anti-CTLA-4 plus anti-PD-1 can partly overcome this adaptive resistance and was recently shown to augment responses in patients with mCRPC with measurable disease. Although bone is the most common site of metastasis in prostate cancer, patients with bone-predominant disease are frequently excluded from trials because they lack measurable disease, which limits assessment of disease progression and tissue sampling. We therefore designed this study to investigate combined ICT in mCRPC to bone.Combined anti-CTLA-4 (tremelimumab) plus anti-PD-L1 (durvalumab) is safe and well tolerated in patients with chemotherapy-naïve mCRPC to bone.In this single-arm pilot study, men with chemotherapy-naïve mCRPC to bone received tremelimumab (75 mg intravenous) plus durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by durvalumab (1500 mg intravenous) maintenance every 4 weeks (up to nine doses). The primary endpoint was incidence of adverse events. Secondary endpoints included serum prostate-specific antigen (PSA), progression-free survival (PFS), radiographic PFS (rPFS), and maximal PSA decline.Twenty-six patients were treated between August 8, 2017 and March 28, 2019. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 11 patients (42%), with no grade 4 or 5 events. TRAEs leading to discontinuation occurred in three patients (12%). PSA decline ≥50% occurred in three patients (12%). Six patients (24%) achieved stable disease for >6 months. At a median follow-up of 43.6 months, median rPFS was 3.7 months (95% CI: 1.9 to 5.7), and median overall survival was 28.1 months (95% CI: 14.5 to 37.3). Post-treatment evaluation of the bone microenvironment revealed transcriptional upregulation in myeloid and neutrophil immune subset signatures and increased expression of inhibitory immune checkpoints.Tremelimumab plus durvalumab was safe and well tolerated in patients with chemotherapy-naïve mCRPC to bone, with potential activity in a small number of patients as measured by rPFS. Combination of CTLA-4 and PD-L1 blockade with therapies targeting the myeloid compartment or other inhibitory immune receptors may be necessary to overcome mechanisms of resistance within prostate bone microenvironment.NCT03204812." @default.
• W3206647534 created "2021-10-25" @default.
• W3206647534 creator A5002666746 @default.
• W3206647534 creator A5008820123 @default.
• W3206647534 creator A5021183845 @default.
• W3206647534 creator A5021224140 @default.
• W3206647534 creator A5026202651 @default.
• W3206647534 creator A5036742367 @default.
• W3206647534 creator A5047117233 @default.
• W3206647534 creator A5047330975 @default.
• W3206647534 creator A5056577711 @default.
• W3206647534 creator A5062740919 @default.
• W3206647534 creator A5064530138 @default.
• W3206647534 creator A5071033599 @default.
• W3206647534 creator A5078144632 @default.
• W3206647534 date "2021-10-01" @default.
• W3206647534 modified "2023-10-17" @default.
• W3206647534 title "Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment" @default.
• W3206647534 cites W1963783520 @default.
• W3206647534 cites W1979811833 @default.
• W3206647534 cites W2075137329 @default.
• W3206647534 cites W2080388405 @default.
• W3206647534 cites W2105949723 @default.
• W3206647534 cites W2150865892 @default.
• W3206647534 cites W2155846302 @default.
• W3206647534 cites W2159771669 @default.
• W3206647534 cites W2214621962 @default.
• W3206647534 cites W2256034989 @default.
• W3206647534 cites W2296253991 @default.
• W3206647534 cites W2531934133 @default.
• W3206647534 cites W2595314544 @default.
• W3206647534 cites W2603526557 @default.
• W3206647534 cites W2768499948 @default.
• W3206647534 cites W2784868445 @default.
• W3206647534 cites W2787804990 @default.
• W3206647534 cites W2792937256 @default.
• W3206647534 cites W2808021061 @default.
• W3206647534 cites W2809493795 @default.
• W3206647534 cites W2902568381 @default.
• W3206647534 cites W2921611058 @default.
• W3206647534 cites W2944289287 @default.
• W3206647534 cites W2947829857 @default.
• W3206647534 cites W2952406594 @default.
• W3206647534 cites W2976744492 @default.
• W3206647534 cites W2977890115 @default.
• W3206647534 cites W2981443129 @default.
• W3206647534 cites W2982970399 @default.
• W3206647534 cites W2984186351 @default.
• W3206647534 cites W2990771207 @default.
• W3206647534 cites W2997072492 @default.
• W3206647534 cites W3014592760 @default.
• W3206647534 cites W3021442601 @default.
• W3206647534 cites W3021646013 @default.
• W3206647534 cites W3029507746 @default.
• W3206647534 cites W3035132440 @default.
• W3206647534 cites W3043703771 @default.
• W3206647534 cites W3046152640 @default.
• W3206647534 cites W3049720236 @default.
• W3206647534 cites W3083447616 @default.
• W3206647534 cites W3083951977 @default.
• W3206647534 cites W3129719839 @default.
• W3206647534 cites W3162381463 @default.
• W3206647534 doi "https://doi.org/10.1136/jitc-2021-002919" @default.
• W3206647534 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8524287" @default.
• W3206647534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34663638" @default.
• W3206647534 hasPublicationYear "2021" @default.
• W3206647534 type Work @default.
• W3206647534 sameAs 3206647534 @default.
• W3206647534 citedByCount "23" @default.
• W3206647534 countsByYear W32066475342021 @default.
• W3206647534 countsByYear W32066475342022 @default.
• W3206647534 countsByYear W32066475342023 @default.
• W3206647534 crossrefType "journal-article" @default.
• W3206647534 hasAuthorship W3206647534A5002666746 @default.
• W3206647534 hasAuthorship W3206647534A5008820123 @default.
• W3206647534 hasAuthorship W3206647534A5021183845 @default.
• W3206647534 hasAuthorship W3206647534A5021224140 @default.
• W3206647534 hasAuthorship W3206647534A5026202651 @default.
• W3206647534 hasAuthorship W3206647534A5036742367 @default.
• W3206647534 hasAuthorship W3206647534A5047117233 @default.
• W3206647534 hasAuthorship W3206647534A5047330975 @default.
• W3206647534 hasAuthorship W3206647534A5056577711 @default.
• W3206647534 hasAuthorship W3206647534A5062740919 @default.
• W3206647534 hasAuthorship W3206647534A5064530138 @default.
• W3206647534 hasAuthorship W3206647534A5071033599 @default.
• W3206647534 hasAuthorship W3206647534A5078144632 @default.
• W3206647534 hasBestOaLocation W32066475341 @default.
• W3206647534 hasConcept C121608353 @default.
• W3206647534 hasConcept C126322002 @default.
• W3206647534 hasConcept C143998085 @default.
• W3206647534 hasConcept C203014093 @default.
• W3206647534 hasConcept C21705690 @default.
• W3206647534 hasConcept C2776090121 @default.
• W3206647534 hasConcept C2776107976 @default.
• W3206647534 hasConcept C2776551883 @default.
• W3206647534 hasConcept C2777701055 @default.
• W3206647534 hasConcept C2777742743 @default.
• W3206647534 hasConcept C2777783956 @default.

• next